secwatch.observer — SEC 8-K summary
======================================

Issuer:     ULTRALIFE CORP (ULBI)
CIK:        0000875657
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001437749-25-035515
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultralife Q3 sales up 21.5% to $43.4M; GAAP loss per share of $0.07 on Calgary closure charge
--------------------------------------------------------------------------------

- Sales $43.4M (+21.5% YoY, including Electrochem); organic growth 2.5%. Backlog $90.1M vs $84.5M at Q2 2025.
- GAAP EPS ($0.07) vs $0.02; operating loss $1.0M includes $1.1M non-recurring costs (Calgary facility closure).
- Gross margin 22.2% down from 24.3% on raw material quality issues; adjusted EBITDA $2.0M vs $1.9M.
- Battery & Energy Products sales +22.8% (ex-Electrochem +1.9%); government/defense sales +19.0%.
- Calgary closure charge $0.5M; expected annual savings ~$0.8M after completion in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875657/000143774925035515/0001437749-25-035515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875657/000143774925035515/ulbi20251117_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-035515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer